345 related articles for article (PubMed ID: 29032459)
1. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.
Langlois F; Lim DST; Yedinak CG; Cetas I; McCartney S; Cetas J; Dogan A; Fleseriu M
Pituitary; 2018 Feb; 21(1):32-40. PubMed ID: 29032459
[TBL] [Abstract][Full Text] [Related]
2. Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases.
Zhang K; Shou X; Chen H; Qiao N; He W; Chen Z; Shen M; Li S; Zhao Y; Zhang Z; Li Y; Ye H; Wang Y
Front Endocrinol (Lausanne); 2020; 11():608691. PubMed ID: 33584540
[TBL] [Abstract][Full Text] [Related]
3. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.
Cooper O; Ben-Shlomo A; Bonert V; Bannykh S; Mirocha J; Melmed S
Horm Cancer; 2010 Apr; 1(2):80-92. PubMed ID: 20717480
[TBL] [Abstract][Full Text] [Related]
4. Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas.
Ioachimescu AG; Eiland L; Chhabra VS; Mastrogianakis GM; Schniederjan MJ; Brat D; Pileggi AV; Oyesiku NM
Neurosurgery; 2012 Aug; 71(2):296-303; discussion 304. PubMed ID: 22517250
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas.
Jahangiri A; Wagner JR; Pekmezci M; Hiniker A; Chang EF; Kunwar S; Blevins L; Aghi MK
Neurosurgery; 2013 Jul; 73(1):8-17; discussion 17-8. PubMed ID: 23685641
[TBL] [Abstract][Full Text] [Related]
6. Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas.
Kim D; Ku CR; Park SH; Moon JH; Kim EH; Kim SH; Lee EJ
World Neurosurg; 2018 Jul; 115():e464-e471. PubMed ID: 29678704
[TBL] [Abstract][Full Text] [Related]
7. Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience.
Langlois F; Lim DST; Varlamov E; Yedinak CG; Cetas JS; McCartney S; Dogan A; Fleseriu M
Endocrine; 2017 Dec; 58(3):528-534. PubMed ID: 29043561
[TBL] [Abstract][Full Text] [Related]
8. Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system.
Jiang S; Zhu J; Feng M; Yao Y; Deng K; Xing B; Lian W; Wang R; Bao X
Pituitary; 2021 Aug; 24(4):564-573. PubMed ID: 33651318
[TBL] [Abstract][Full Text] [Related]
9. Clinical, Laboratory, and Treatment Profiles of Silent Corticotroph Adenomas That Have Transformed to the Functional Type: A Case Series With a Literature Review.
Zheng G; Lu L; Zhu H; You H; Feng M; Liu X; Dai C; Yao Y; Wang R; Zhang H; Sun X; Lu Z
Front Endocrinol (Lausanne); 2020; 11():558593. PubMed ID: 33071973
[No Abstract] [Full Text] [Related]
10. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.
Raverot G; Wierinckx A; Jouanneau E; Auger C; Borson-Chazot F; Lachuer J; Pugeat M; Trouillas J
Eur J Endocrinol; 2010 Jul; 163(1):35-43. PubMed ID: 20385723
[TBL] [Abstract][Full Text] [Related]
11. Silent corticotroph adenomas.
Cooper O
Pituitary; 2015 Apr; 18(2):225-31. PubMed ID: 25534889
[TBL] [Abstract][Full Text] [Related]
12. Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery-a retrospective, single-center study.
Sumislawski P; Huckhagel T; Krajewski KL; Aberle J; Saeger W; Flitsch J; Rotermund R
Sci Rep; 2023 Feb; 13(1):2468. PubMed ID: 36774403
[TBL] [Abstract][Full Text] [Related]
13. Complications after transsphenoidal surgery for patients with Cushing's disease and silent corticotroph adenomas.
Smith TR; Hulou MM; Huang KT; Nery B; de Moura SM; Cote DJ; Laws ER
Neurosurg Focus; 2015 Feb; 38(2):E12. PubMed ID: 25639314
[TBL] [Abstract][Full Text] [Related]
14. Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence.
Strickland BA; Shahrestani S; Briggs RG; Jackanich A; Tavakol S; Hurth K; Shiroishi MS; Liu CJ; Carmichael JD; Weiss M; Zada G
J Neurosurg; 2021 May; 135(6):1706-1713. PubMed ID: 33962375
[TBL] [Abstract][Full Text] [Related]
15. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas.
Cho HY; Cho SW; Kim SW; Shin CS; Park KS; Kim SY
Clin Endocrinol (Oxf); 2010 May; 72(5):648-53. PubMed ID: 19650787
[TBL] [Abstract][Full Text] [Related]
16. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently.
Bradley KJ; Wass JA; Turner HE
Clin Endocrinol (Oxf); 2003 Jan; 58(1):59-64. PubMed ID: 12519413
[TBL] [Abstract][Full Text] [Related]
17. ACTH adenomas transforming their clinical expression: report of 5 cases.
Zoli M; Faustini-Fustini M; Mazzatenta D; Marucci G; De Carlo E; Bacci A; Pasquini E; Lanzino G; Frank G
Neurosurg Focus; 2015 Feb; 38(2):E15. PubMed ID: 25639317
[TBL] [Abstract][Full Text] [Related]
18. Silent corticotroph adenomas.
Ben-Shlomo A; Cooper O
Pituitary; 2018 Apr; 21(2):183-193. PubMed ID: 29344907
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [Review].
Kageyama K; Oki Y; Nigawara T; Suda T; Daimon M
Endocr J; 2014; 61(10):941-8. PubMed ID: 24974880
[TBL] [Abstract][Full Text] [Related]
20. A clinicoradiological analysis of silent corticotroph adenomas after the introduction of pituitary-specific transcription factors.
Goyal-Honavar A; Sarkar S; Asha HS; Kapoor N; Balakrishnan R; Vanjare H; Chacko G; Chacko AG
Acta Neurochir (Wien); 2021 Nov; 163(11):3143-3154. PubMed ID: 34181087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
